GlaxoSmithKline: exercices option with T-cell tumour therapy
(CercleFinance.com) - GlaxoSmithKline has exercised the option to obtain an exclusive global license from British biotech firm Adaptimmune for an investigational cell therapy that targets tumours.
Upon exercise of the option, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the T-cell receptor therapy.
"This news is good news for GSK, as it marks its entry in the Adoptive T-cell therapy space, with the NY-ESO TCR programme currently in phase I/II for the synovial sarcoma, myxoid round cell liposarcoma, ovarian cancer, melanoma, NSCLC and multiple myeloma," analysts at Bryan Garnier commented.
"As such, we can say that GSK is not so far behind other EU players under our coverage in the cellular therapy field, such as Celyad or Cellectis," the brokerage firm added.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Upon exercise of the option, GSK will assume responsibility for all development, manufacturing and commercialisation activities for the T-cell receptor therapy.
"This news is good news for GSK, as it marks its entry in the Adoptive T-cell therapy space, with the NY-ESO TCR programme currently in phase I/II for the synovial sarcoma, myxoid round cell liposarcoma, ovarian cancer, melanoma, NSCLC and multiple myeloma," analysts at Bryan Garnier commented.
"As such, we can say that GSK is not so far behind other EU players under our coverage in the cellular therapy field, such as Celyad or Cellectis," the brokerage firm added.
Copyright (c) 2017 CercleFinance.com. All rights reserved.